Decibel Therapeutics
Cambridge
About Decibel Therapeutics
Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $189.2M
- Funding stage: M&A
- Last round: Series D (Nov 2020)
- Ticker: nasdaq:DBTX
- Website: decibeltx.com
- Phone: (617) 370-8701
Industries & Categories
Biotechnology, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/decibel-therapeutics-36461 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.